Latest Neuroblastoma Stories

Administering a new form of immunotherapy to children with neuroblastoma, a nervous system cancer, increased the percentage of those who were alive and free of disease progression after two years, according to researchers at the University of California, San Diego School of Medicine and fellow institutions. The percentage rose from 46 percent for children receiving a standard therapy to 66 percent for children receiving immunotherapy plus standard therapy, according to the study published in...

A particularly aggressive childhood cancer can be fought successfully with far less chemotherapy than previously believed, avoiding harmful side effects caused by cancer drugs.The 96 percent survival rate found in an eight-year clinical trial at the University of California, San Francisco, stands to change the approach toward fighting intermediate-risk "“ stage three and stage four "“ neuroblastoma. Neuroblastoma attacks the network of cells that control the body's response to stress,...

New standard of care in high-risk neuroblastoma seen in immunotherapy resultsUsing immunotherapy"”biologic agents that stimulate the body's immune system"”pediatric oncologists have achieved the first substantial increase in over a decade in cure rates for the childhood cancer neuroblastoma. A newly released study shows that the new treatment improved two-year survival rates by 20 percent, compared to standard treatment for an aggressive form of neuroblastoma, a cancer of the nervous...

-- New Standard of Care in High-Risk Neuroblastoma Seen in Immunotherapy Results-- PHILADELPHIA, Sept. 29 /PRNewswire-USNewswire/ -- Using immunotherapy--biologic agents that stimulate the body's immune system--pediatric oncologists have achieved the first substantial increase in over a decade in cure rates for the childhood cancer neuroblastoma. A newly released study shows that the new treatment improved survival rates by 20 percent, compared to standard treatment for an aggressive form...

All amounts are in U.S. dollars QUEBEC CITY, Aug. 12 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) ("the Company"), a late-stage drug development company specialized in oncology and endocrinology, today reported financial and operating results for the second quarter ended June 30, 2010. Second Quarter 2010 Highlights Pipeline development Perifosine - April 5, 2010: Perifosine receives U.S. Food and Drug Administration ("FDA") Fast Track...

QUEBEC CITY, July 14 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company"), a late-stage drug development company specialized in oncology and endocrine therapy, today announced that its partner, Keryx Biopharmaceuticals, Inc. ("Keryx") (Nasdaq: KERX), has been granted orphan-drug designation by the U.S. Food and Drug Administration ("FDA") for perifosine, Aeterna Zentaris' novel, potentially first-in-class, oral Akt inhibitor, for the treatment of...

NEW YORK, July 14 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that KRX-0401 (perifosine) has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of neuroblastoma, a cancer of the nervous system affecting mostly children and infants for which there are no FDA approved therapies. Phase 1 data of perifosine in recurrent pediatric solid tumors, including neuroblastoma, was presented last month in the...

CHOP oncology chief working to translate his lab's genetic findings into treatmentsPediatric oncologist John M. Maris, M.D., describes the current state of the science in combating neuroblastoma, the most common solid cancer of early childhood. In his article in the June 10, 2010 New England Journal of Medicine, "Recent Advances in Neuroblastoma," Maris reviews the field's latest research knowledge"”much of it based on efforts by Maris and his colleagues at The Children's Hospital...

--CHOP Oncology Chief Working to Translate His Lab's Genetic Findings into Treatments-- PHILADELPHIA, June 14 /PRNewswire-USNewswire/ -- Pediatric oncologist John M. Maris, M.D., describes the current state of the science in combating neuroblastoma, the most common solid cancer of early childhood. In his article in the June 10, 2010 New England Journal of Medicine, "Recent Advances in Neuroblastoma," Maris reviews the field's latest research knowledge--much of it based on efforts by Maris...

--In Colket Building, Scientists Will Translate Research into Real-Life Treatments for Children -- PHILADELPHIA, June 9 /PRNewswire-USNewswire/ -- The Children's Hospital of Philadelphia will dedicate its new Ruth and Tristram Colket, Jr. Translational Research Building on Wednesday, June 9, at 11 a.m. Launched with an initial gift of $25 million from Ruth M. and Tristram C. Colket, Jr., the 12-story, environmentally friendly structure houses high-profile, cutting-edge programs for...